BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 38040418)

  • 1. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment
    Xu W; Lu J; Liu WR; Anwaier A; Wu Y; Tian X; Su JQ; Qu YY; Yang J; Zhang H; Ye D
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma.
    Xu W; Ma C; Liu W; Anwaier A; Tian X; Shi G; Qu Y; Wei S; Zhang H; Ye D
    Cancer Immunol Immunother; 2022 Aug; 71(8):1923-1935. PubMed ID: 35043231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unveiling the impact of tertiary lymphoid structures on immunotherapeutic responses of clear cell renal cell carcinoma.
    Xu W; Lu J; Tian X; Ye S; Wei S; Wang J; Anwaier A; Qu Y; Liu W; Chang K; Zhang H; Ye D
    MedComm (2020); 2024 Jan; 5(1):e461. PubMed ID: 38222314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer.
    Masuda T; Tanaka N; Takamatsu K; Hakozaki K; Takahashi R; Anno T; Kufukihara R; Shojo K; Mikami S; Shinojima T; Kakimi K; Tsunoda T; Aimono E; Nishihara H; Mizuno R; Oya M
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35314433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma.
    Zhang D; Ni Y; Wang Y; Feng J; Zhuang N; Li J; Liu L; Shen W; Zheng J; Zheng W; Qian C; Shan J; Zhou Z
    J Transl Med; 2023 Jul; 21(1):489. PubMed ID: 37474942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
    Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
    Front Immunol; 2021; 12():734646. PubMed ID: 34795663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors.
    Zhang WH; Wang WQ; Han X; Gao HL; Xu SS; Li S; Li TJ; Xu HX; Li H; Ye LY; Lin X; Wu CT; Long J; Yu XJ; Liu L
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33055204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral CXCL13
    Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics.
    Ye S; Tian X; Anwaier A; Wei S; Liu W; Su J; Zhu S; Dai B; Gu J; Qu Y; Xu W; Zhang H; Ye D
    Int J Biol Sci; 2023; 19(14):4552-4570. PubMed ID: 37781030
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma.
    Xu W; Wu Y; Liu W; Anwaier A; Tian X; Su J; Huang H; Wei G; Qu Y; Zhang H; Ye D
    Int J Biol Sci; 2022; 18(13):4884-4900. PubMed ID: 35982911
    [No Abstract]   [Full Text] [Related]  

  • 11. Deciphering the implications of mitophagy-related signatures in clinical outcomes and microenvironment heterogeneity of clear cell renal cell carcinoma.
    Xiang J; Liu W; Liu S; Wang T; Tang H; Yang J
    J Cancer Res Clin Oncol; 2023 Nov; 149(17):16015-16030. PubMed ID: 37689589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.
    Carril-Ajuria L; Desnoyer A; Meylan M; Dalban C; Naigeon M; Cassard L; Vano Y; Rioux-Leclercq N; Chouaib S; Beuselinck B; Chabaud S; Barros-Monteiro J; Bougoüin A; Lacroix G; Colina-Moreno I; Tantot F; Boselli L; De Oliveira C; Fridman WH; Escudier B; Sautes-Fridman C; Albiges L; Chaput-Gras N
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of mature tertiary lymphoid structures on prognosis and therapeutic response of Epstein-Barr virus-associated gastric cancer patients.
    Yin YX; Ling YH; Wei XL; He CY; Wang BZ; Hu CF; Lin WP; Nie RC; Chen JW; Lin JL; Zhou J; Xie JJ; Yun JP; Xie D; Xue LY; Cai MY
    Front Immunol; 2022; 13():973085. PubMed ID: 36591236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction values of tertiary lymphoid structures in the prognosis of patients with left- and right-sided colon cancer: a multicenter propensity score-matched study.
    Mao Y; Wang X; Xi L; Dong M; Song P; Miao J; Lu C; Sun S; Li Q; Yu C; Shen X
    Int J Surg; 2023 Aug; 109(8):2344-2358. PubMed ID: 37247038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma.
    Lynch KT; Young SJ; Meneveau MO; Wages NA; Engelhard VH; Slingluff CL; Mauldin IS
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative analysis of tertiary lymphoid structures and immune microenvironment in patients with esophageal carcinoma.
    Yao Y; Xuan H; Wang J; Gong L; Gao W
    Tumori; 2023 Oct; 109(5):466-480. PubMed ID: 37249074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
    Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
    J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm.
    Luo J; Xie Y; Zheng Y; Wang C; Qi F; Hu J; Xu Y
    Cancer Med; 2020 Jun; 9(12):4310-4323. PubMed ID: 32311223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crosstalk of necroptosis and pyroptosis defines tumor microenvironment characterization and predicts prognosis in clear cell renal carcinoma.
    Fu L; Bao J; Li J; Li Q; Lin H; Zhou Y; Li J; Yan Y; Langston ME; Sun T; Guo S; Zhou X; Chen Y; Liu Y; Zhao Y; Lu J; Huang Y; Chen W; Chung BI; Luo J
    Front Immunol; 2022; 13():1021935. PubMed ID: 36248876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
    Gao J; Ye F; Han F; Jiang H; Zhang J
    Front Immunol; 2022; 13():956679. PubMed ID: 36177018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.